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Abstract
Background: Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral
therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.
Methods and Findings: Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010
merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated
episodes of viral suppression for each patient while on cART, each episode beginning with the second of two consecutive
plasma viral load measurements ,50 copies/ml and ending with either a measurement .500 copies/ml, the first of two
consecutive measurements between 50–500 copies/ml, cART interruption or administrative censoring. We used stratified
multivariate Cox models to estimate the association between time updated CD4 cell count and a new AIDS event or death
or death alone. 75,336 patients contributed 104,265 suppression episodes and were suppressed while on cART for a median
2.7 years. The mortality rate was 4.8 per 1,000 years of viral suppression. A higher CD4 cell count was always associated with
a reduced risk of a new AIDS event or death; with a hazard ratio per 100 cells/ml (95% CI) of: 0.35 (0.30–0.40) for counts,200
cells/ml, 0.81 (0.71–0.92) for counts 200 to,350 cells/ml, 0.74 (0.66–0.83) for counts 350 to,500 cells/ml, and 0.96 (0.92–0.99)
for counts $500 cells/ml. A higher CD4 cell count became even more beneficial over time for patients with CD4 cell counts
,200 cells/ml.
Conclusions: Despite the low mortality rate, the risk of a new AIDS event or death follows a CD4 cell count gradient in
patients with viral suppression. A higher CD4 cell count was associated with the greatest benefit for patients with a CD4 cell
count ,200 cells/ml but still some slight benefit for those with a CD4 cell count $500 cells/ml.
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Introduction
More than 90% of those infected with HIV now achieve viral
suppression within a year of starting a combination antiretroviral
therapy (cART) [1,2]. Patients with a suppressed viral load now
represent the majority of cART recipients. Previous cohort studies
have shown that the CD4 cell count when starting cART is the
most important prognostic factor for clinical outcome, but these
studies have focused on cART-naı¨ve patients and have ignored
treatment changes and periods of detectable viral load [3,4].
This study considers the prognostic value of a CD4 cell count, not
when starting cART, but while a patient is being successfully
treated, that is, while a patient is on cART with a suppressed viral
load. For many patients, viral suppression is not continuous but
episodic with periods of viremia as a result of treatment interruption
or treatment failure. We selected patients from the Collaboration of
Observational HIV Epidemiological Research in Europe (CO-
HERE) database, accumulated episodes of viral suppression for
each patient while on cART, and used these episodes to estimate the
association between a time updated CD4 cell count and progression
to a new AIDS-defining event or death, or death alone.
Methods
The COHERE Collaboration
COHERE is a collaboration of European HIV cohorts (http://
www.cohere.org/). The 22 cohorts participating in this project
provided data in a standardised format to one of two regional co-
ordinating centres, where basic error checks were carried out and
duplicate records removed for patients followed in more than one
cohort. Data collected included information on patient character-
istics, antiretroviral therapy, CD4 cell count, HIV RNA viral load,
AIDS events, and causes of death. This analysis was based on data
merged in 2010 when, for the first time, additional data were
collected on co-infection with and treatment for hepatitis B or C,
and on the prophylaxis and treatment of opportunistic infections.
Patients included in the 2010 merger had to have this additional
information and follow-up after 1 January 1997.
Patient Inclusion
Patients were eligible for our analyses if they achieved one or
more episodes of viral suppression while on cART. Optimal viral
suppression is defined as a viral load below the level of detection or
below 20–75 copies/ml depending on the assay used; however,
isolated transient detectable viral loads below 400 copies/ml are
not uncommon in successfully treated patients and are not thought
to represent an increased risk of virologic failure [5]. We defined
the start of a suppression episode as the second of two consecutive
viral load measurements below 50 copies/ml (or below the limit of
detection) while on cART. We defined the end of a suppression
episode as a viral load measurement below 50 copies/ml (or
undetectable) then followed by either (1) a measurement greater
than 500 copies/ml, (2) the first of two consecutive measurements
between 50 and 500 copies/ml, (3) an interruption in cART, or (4)
no further viral load measurements. Note that our definition
allows for isolated viral load measurements of between 50 and 500
copies/ml within a suppression episode. We defined cART as any
three antiretroviral drugs from any drug class, except that three
nucleoside (or nucleotide) reverse-transcriptase inhibitors (NRTIs)
was only considered cART if taken after another cART regimen.
Patients with at least one suppression episode were then included in
our time to event analyses if pre-specified covariates were also
available. Patients had to have a CD4 cell count measured within 6
mo prior to the start of an episode or within an episode, and CD4 cell
counts were updated over time in our analyses so that each episode
was represented by a set of intervals, one interval per CD4 cell count,
using the counting process method of representing time to event data.
Patients with more than one suppression episode contributed more
than one set of intervals to our analyses, but were not at risk between
episodes (see [6]). We deleted any interval where the CD4 cell count
was measured before the patient was 16 y old. Other covariates were
age (in the year 2000), gender, intravenous drug use as the likely mode
of HIV transmission, viral load, co-infection with hepatitis B or C,
cART category, and the number of prior cART regimens, with these
last three covariates updated for each interval. For a first suppression
episode, we used a last viral load prior to starting cART as the viral
load covariate; for a subsequent episode, we used the highest viral load
between the previous and current episode as the covariate.
Statistical Methods
Our primary outcome was time to a first new AIDS event or
death while suppressed and on cART, with an AIDS event defined
as one of the conditions listed in Appendix B of the 1993 US
Centers for Disease Control (CDC) AIDS surveillance case
definition [7]. We used Cox proportional hazards models to
estimate the association between an AIDS event or death and
CD4 cell count, with CD4 cell count represented by a linear spline
with three knots at 200, 350, and 500 cells/ml [8]. These knots
correspond to thresholds in treatment guidelines below; below
these three thresholds, antiretroviral treatment is essential,
recommended, or should be considered, respectively [5]. A hazard
ratio (HR) ,1.0 for any of the four components of this spline
implies that a higher CD4 cell count (per 100 cells/ml) is associated
with a lower risk of progression and is therefore a measure of the
benefit that a patient can expect if their CD4 cell count increases
above any current level within the range covered by that spline
component. Our models included the baseline and time updated
covariates described above. We stratified our models by cohort, so
that each cohort had its own non-parametric baseline hazard
function, but we assumed the effect of each covariate was the same
in each cohort [9]. To assess whether the hazards associated with
CD4 cell count were constant over time (i.e., proportional
hazards), we fitted a model with interaction terms between log
suppression time and CD4 cell count, with these interactions
centred around the geometric mean suppression time [10–12].
We carried out six planned sensitivity analyses to check that our
estimates were stable. Assays have become more sensitive over time,
so we re-fitted our model with (1) a suppression episode re-defined as
a viral load below 400 copies/ml—to simulate constant use over
time of a less sensitive assay; and (2) with the analysis restricted to
suppression episodes starting after 1 January 2001—to largely omit
episodes found using less sensitive assays [13]. We varied the period
of time after a last viral load measurement within which new AIDS
events or death were accepted as outcomes if suppression was
ongoing. We considered such events as outcomes if they occurred
within 180 d of a last viral load where the patient was still
suppressed at this last measurement, but in sensitivity analyses we
re-fitted our model assuming (3) shorter and (4) longer periods (90
and 270 d, respectively). We dropped covariates from our model to
retain episodes lost from our analyses because of missing covariates.
We re-fitted our model (5) without viral load as a covariate because
for many patients, we did not have a viral load measured prior to
starting cART; and (6) without co-infection with hepatitis as a
covariate, because then we could include additional patients in our
analysis from the 2008 merger of the COHERE database [14].
Finally in a single unplanned sensitivity analysis, we assessed
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whether the risk of progression differed between first and
subsequent episodes of viral suppression. We added an additional
covariate to the analysis of the primary outcome, either taking value
zero for a first suppression episode and one otherwise, or taking
value zero for a first suppression episode and the number of years
between successive episodes otherwise.
Our secondary outcome was time to death while both
suppressed and on cART. We classified a death as ‘‘related to
HIV’’ if death was attributed at least in part to an ‘‘AIDS defining
event’’ or an ‘‘invasive bacterial infection.’’ If these two causes
were not mentioned but other causes of death were given, we
classified a death as ‘‘unrelated to HIV.’’ If no causes of death
were given, we classified a death as of ‘‘unknown cause.’’ We then
fitted a Cox model with different cause-specific hazards for CD4
cell count [15], again with CD4 cell count represented by a linear
spline and with the same covariates as before.
Analyses were carried out with the PHREG procedure in SAS
version 9.2; survival curves were plotted with the Survival package
version 2.36-2 in R version 2.12.1. We report model estimates as
HRs, each with a 95% CI.
Table 1. COHERE patients with continuous or episodic viral suppression while on cART.
Patient Characteristics Included (n=66,147) Excluded (n=110,438)
Age at 2,000, y, median (IQR) 37 (32–44) 35 (28–41)
Percent female 27 29
Percent ever diagnosed with AIDS 26 25
Percent transmission by drug use 14 17
Percent recorded as of European nationalitya 43 34
Year first suppression episode began, median (IQR) 2003 (2000–2006)
CD4 cell count, cells/ml, median (IQR)b 396 (256–565)
HIV RNA viral load, log 10 copies/ml, median (IQR)c 4.6 (3.5–5.2)
Percent hepatitis B or Cb 9
Percent cART categoryb
NNRTI 34
PI boosted with ritonavir 30
PI without ritonavir 25
Otherd 11
Percent CD4 cell category, cells/mlb
,50 1
50 to ,200 15
200 to ,350 26
350 to ,500 25
$500 34
Note that the number of patients included in the main analyses of primary and secondary outcomes (n= 66,147) is lower than the number of patients in Tables 2–4 with
at least one suppression episode (n= 75,336) because viral load prior to starting cART was not known for some patients.
aNationality was not recorded for 40% of patients included in these analyses and for 50% of patients excluded from these analyses.
bAt the start of a first suppression episode. Note that 103 patients that did not contribute a first episode to the main analyses because either no CD4 cell counts were
available for this episode or this episode occurred while the patient was still under the age of 16.
cLast viral load before starting combination therapy. Note that a further 4,211 patients did not contribute a first episode to the main analyses because their viral load
before starting combination therapy was not known (although these patients contributed a first episode to the sensitivity analysis without this covariate).
dOther: at least one protease inhibitor (PI) and one non-nucleoside reverse-transcriptase inhibitor (NNRTI), 5%; three NRTIs, 3%; at least two PIs (other than ritonavir) but
no NNRTI, 2%; any therapy including integrase or fusion inhibitors, 1%.
doi:10.1371/journal.pmed.1001194.t001
Table 2. Event rates in CD4 strata among the 75,336 patients with at least one suppression episode while on cART: event rates per
1,000 y of suppressed viral load (number of events) by outcome.
Most Recent CD4
Cell Count (Cells/ml)
First New AIDS Event or
Death from Any Cause
Death from
Any Cause
Death from Causes
Unrelated to HIV
,50 94.9 (54) 64.8 (38) 25.6 (15)
50 to ,200 30.5 (489) 20.0 (325) 14.1 (230)
200 to ,350 12.0 (548) 6.9 (318) 5.2 (240)
350 to ,500 7.9 (487) 3.8 (240) 2.9 (184)
$500 5.2 (679) 2.4 (315) 1.9 (253)
doi:10.1371/journal.pmed.1001194.t002
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Results
Patient Characteristics
Of the 176,585 patients in the 2010 merger of COHERE,
75,336 patients provided 104,265 suppression episodes while on
cART (Text S1); 71% of these patients had just a single episode.
The median length of a suppression episode was 1.7 y (inter-
quartile range [IQR] 0.7–3.5); the median total time suppressed
while on cART was 2.7 y (IQR 1.2–5.1) per patient; the estimated
average gain in CD4 cell count while suppressed was 53 cells/ml
per year. The main analyses of primary and secondary outcomes
were based on 66,147 patients with a viral load measured prior to
starting cART. Patients contributing to our main analyses tended
to be slightly older, were less likely to be either female or infected
through drug use, and were more likely to be recorded as of
European origin than other patients in this merger of COHERE
(Table 1). Few patients (1%) started their first suppression episode
with a CD4 cell count below 50 cells/ml and many (34%) started
with a CD4 cell count above 500 cells/ml.
Event Rates
The rate of progression to a first new AIDS event or death was
8.9 per 1,000 y of suppression; the mortality rate was 4.8 per
1,000 y of suppression. Both rates showed a gradient that depends
on CD4 cell count with the highest rates in those with ,50 CD4
cells/ml at the time of the event (Table 2). Even mortality from
causes thought unrelated to HIV (Table 2) and the rate of HIV
related neoplasms (Table 3) increased with decreasing CD4 cell
count. The rate of progression to a first new AIDS event or death
decreased over time in all CD4 strata (Table 4), except where
patients had a low CD4 cell count (0 to ,200 CD4 cells/ml).
A time updated Kaplan Meier plot illustrates the relatively low
probability of AIDS event-free survival—roughly 70% after 10 y
of suppression—should a patient’s CD4 cell count remain below
200 cells/ml while suppressed (Figure 1A) [16]. In contrast, the
probability of AIDS event-free survival was roughly 95% after
10 y of suppression for patients maintaining a CD4 cell count of
500 cells/ml or more while suppressed. It is important to note that
CD4 cell count was time dependent and updated when calculating
these probabilities. Therefore this plot shows probabilities for
hypothetical patients whose CD4 count remains within the same
CD4 stratum while suppressed [16]. The roughly parallel lines in
the plot of AIDS event-free survival (log log scale) against time (log
scale) suggest that a proportional hazards model was appropriate
for these data (Figure 1B) [11,12].
Time to AIDS or Death
A Cox proportional hazards model for time to a first new AIDS
event or death also showed a gradient that depends on CD4 cell
count (Table 5). A higher CD4 cell count was associated with a
much greater decrease in the risk of progression when a patient
had a CD4 cell count below 200 cells/ml (HR 0.35, 0.30–0.40, per
100 cells/ml) than when a patient had a CD4 cell count above 500
cells/ml. However, even at a CD4 cell count above 500 cells/ml, a
higher CD4 cell count was associated with a slightly reduced risk
of progression (HR 0.96, 0.92–0.99, per 100 cells/ml). A higher
CD4 cell count had intermediate benefit for CD4 cell counts in the
range from 200 to 350 and from 350 to 500 cells/ml.
The same model suggests that progression was more likely for
older patients (HR 1.42, 1.36–1.49, per 10 y), for those infected by
drug use (HR 1.95, 1.73–2.2), and for those with hepatitis B or C
(HR 1.26, 1.05–1.51). Progression was also more likely for patients
on cART regimens typically used after virologic failure (boosted
protease inhibitor or other cART) compared to non-NRTI-based
cART (the reference category).
Plots of weighted Schoenfeld residuals (not shown) suggest a
proportional hazards assumption was reasonable for these data [11].
However we also fitted a reduced model, with CD4 cell count
represented by a linear spine with a just single knot at 200 cells/ml
and with interaction terms between each of the two components of
this spline and log suppression time. For patients with a CD4 cell
count below 200 cells/ml (HR 0.21, 0.19–0.24, per 100 cells/ml), the
interaction (HR 0.51, 0.48–0.54) implied that with a higher CD4
cell count, the risk of progression was not constant but decreased
over time. For patients with a CD4 cell count above 200 cells/ml
(HR 0.92, 0.90–0.94, per 100 cells/ml), the interaction (HR 1.02,
1.00–1.05) implied that the risk of progression was constant over
Table 3. Event rates in CD4 strata among the 75,336 patients with at least one suppression episode while on cART: event rates per
1,000 y of suppressed viral load (number of events) for a first new AIDS event, with each event then classified as either an
opportunistic infection or a HIV related neoplasm.
Most Recent CD4 Cell Count (Cells/ml) First New AIDS Event Opportunistic Infection HIV Related Neoplasm
,50 29.9 (17) 21.1 (12) 8.8 (5)
50 to ,200 10.8 (173) 7.5 (121) 3.2 (51)
200 to ,350 5.2 (239) 3.4 (155) 1.8 (82)
350 to ,500 4.0 (249) 2.5 (153) 1.6 (96)
$500 2.9 (376) 2.0 (256) 0.9 (119)
Four first new AIDS events could not be classified as either an opportunistic infection or an HIV-related neoplasm.
doi:10.1371/journal.pmed.1001194.t003
Table 4. Event rates in CD4 strata among the 75,336 patients
with at least one suppression episode while on cART: event
rates per 1,000 y of suppressed viral load (number of events)
over time for the primary outcome (a first new AIDS event or
death).
Most Recent CD4
Cell Count (Cells/ml) ,1 y 1 to ,2 y $2 y
,50 108.5 (36) 73.2 (7) 77.6 (11)
50 to ,200 35.4 (251) 22.7 (89) 29.7 (149)
200 to ,350 18.2 (247) 9.8 (108) 9.2 (193)
350 to ,500 11.5 (160) 7.6 (105) 6.5 (222)
$500 8.7 (173) 5.3 (128) 4.4 (378)
doi:10.1371/journal.pmed.1001194.t004
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Figure 1. Probability plots of AIDS event-free survival over time. These plots apply to hypothetical patients whose CD4 cell count remains
within the same CD4 stratum while on cART with a suppressed viral load. Plot (A) shows a Kaplan Meier plot of the probability of AIDS event-free
survival over time. Plot (B) shows a plot of log(2log [probability of AIDS event-free survival]) against log(time). The roughly parallel lines of plot (B)
suggest that a proportional hazards model is appropriate for these data. Both plots use a method appropriate for a time-dependent CD4 cell count
(see [16]).
doi:10.1371/journal.pmed.1001194.g001
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time. The increasing benefit over time of a higher CD4 cell count
for patients with low CD4 cell counts is consistent with the increased
event rate after 2 y in Table 4 for patients with low CD4 cell counts
and the slight increase in slope after 2 y in Figure 1B for patients
with low CD4 cell counts.
HRs for the spline representing CD4 cell count were similar in
all six planned sensitivity analyses (Text S1). In the unplanned
sensitivity analysis, there was no evidence that the risk of
progression differed between first and subsequent episodes of viral
suppression (Text S1). The estimated average loss in CD4 cell
count between the end of one suppression episode and the
beginning of the next was 23 cells/ml per year.
Time to Death
A Cox proportional hazards model for time to death from any
cause showed a similar gradient with respect to CD4 cell count
(Table 5). There was, however, no real benefit in a higher CD4
cell count for patients with a CD4 cell count above 500 cells/ml
(HR 0.98, 0.93–1.03, per 100 cells/ml). And, unlike the primary
outcome, women had a lower risk of death (HR 0.77, 0.65–0.90)
and cART with three NRTIs was associated with a higher risk of
death (HR 1.36, 1.06–1.76).
In a competing risks analysis, we fitted a reduced model with
CD4 cell count represented by a linear spine with a just single knot
at 200 cells/ml. For patients with a CD4 cell count below 200
cells/ml, a higher CD4 cell count had the most benefit for deaths
attributed at least in part to HIV and for deaths of unknown cause
(HR 0.20, 0.14–0.30, and 0.22, 0.15–0.32, per 100 cells/ml,
respectively), but still had appreciable benefit for deaths thought
unrelated to HIV (HR 0.32, 0.26–0.38, per 100 cells/ml). For
patients with a CD4 cell count above 200 cells/ml, a higher CD4
cell count had the most benefit for deaths attributed at least in part
to HIV (HR 0.58, 0.49–0.70, per 100 cells/ml), but still had some
benefit for deaths of unknown cause and for deaths thought
unrelated to HIV (HR 0.86, 0.79–0.94, and 0.88, 0.85–0.91, per
100 cells/ml, respectively).
Discussion
This study shows that a higher CD4 cell count is associated with
a reduced risk of clinical progression in patients on cART with a
suppressed viral load. For patients with a low CD4 cell count, a
higher CD4 cell count becomes even more beneficial over time.
The benefits associated with a higher CD4 cell count are similar
for patients with a CD4 cell count either between 200 and 350
cells/ml or between 350 and 500 cells/ml. Even patients with a
CD4 cell count above 500 cells/ml will benefit to a slight extent
from a higher CD4 cell count, although there is little if any
association between this and the risk of death. Absolute risk
reductions in this highest CD4 cell category, however, will be small
at best and of little clinical relevance for most patients.
The benefits seen here appear to apply irrespective of whether
viral suppression is continuous or episodic. Additional results from
the unplanned sensitivity analysis suggest that, having adjusted for
other covariates (including a time updated CD4 cell count),
patients with episodic suppression were no more likely to progress
than patients with continuous suppression. This does not imply
that a period of viremia is without negative consequences. Rather
Table 5. HR estimates and their 95% CIs from multivariate Cox proportional hazard models for both the primary and secondary
outcome in 66,147 patients on cART with a suppressed viral load.
Model Parameter
Primary Outcome: Time to a First New
AIDS Event or Death (1,838 Events)
Secondary Outcome: Time to Death
from Any Cause (1,000 Events)
HR 95% CI HR 95% CI
Age (per 10 y) 1.42 1.36–1.49 1.80 1.70–1.91
Female 0.99 0.88–1.11 0.77 0.65–0.90
Transmission by drug use 1.95 1.73–2.20 2.86 2.45–3.33
Hepatitis B or Ca 1.26 1.05–1.51 1.44 1.11–1.88
Number of prior cART regimensa 0.99 0.97–1.02 1.02 0.99–1.05
HIV RNA (per log 10 copies)b 1.02 0.98–1.06 1.00 0.95–1.05
cART (with NNRTI as the reference category)a
Three NRTIs 1.14 0.93–1.39 1.36 1.06–1.76
PI without ritonavir 1.08 0.93–1.25 1.19 0.98–1.46
PI boosted with ritonavir 1.17 1.04–1.32 1.13 0.95–1.33
Otherc 1.25 1.05–1.48 1.37 1.10–1.71
CD4 cell count (per 100 cells/ml) as a linear splined
0 to ,200 0.35 0.30–0.40 0.32 0.27–0.39
200 to ,350 0.81 0.71–0.92 0.75 0.63–0.89
350 to ,500 0.74 0.66–0.83 0.68 0.58–0.80
$500 0.96 0.92–0.99 0.98 0.93–1.03
aTime-dependent covariate.
bLast viral load prior to starting cART or highest viral load recorded between episodes.
cOther: at least one protease inhibitor (PI) and one non-nucleoside reverse-transcriptase inhibitor (NNRTI), at least two PIs (other than ritonavir) but no NNRTI; any
therapy including integrase or fusion inhibitors.
dTime-dependent covariate. A HR,1.0 for any of the four components of this spline implies that a higher CD4 cell count (per 100 cells/ml) is associated with a lower risk
of progression and is therefore a measure of the benefit that a patient can expect if their CD4 cell count increases above any current level within the range covered by
that spline component.
doi:10.1371/journal.pmed.1001194.t005
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these results are consistent with immunological and epidemiolog-
ical evidence that the negative consequences of viremia are
damage to the immune system and a subsequent decline in CD4
cell count [17–20]. For those patients with more than one episode
of viral suppression, the estimated loss in CD4 cell count between
the end of one suppression episode and the beginning of the next
was 23 cells/ml per year.
Our estimates of the benefit associated with a higher CD4 cell
count have relatively narrow CIs, are robust across sensitivity
analyses, and show logical differences between different outcomes
and different causes of death. Although many patients were
excluded from this merger of COHERE or from the main analysis
because of missing covariate information, sensitivity analyses
without these covariates and with these patients included suggest
that these exclusions have not had a material effect on estimates.
We used time updated CD4 cell count to model the risk of
progression because in clinical practice decisions are based on the
most recent data [10,21]. We would underestimate the benefit of a
higher CD4 cell count were we to base an analysis on the CD4 cell
count at the beginning of a suppression episode because of the
decay over time in the predictive value of a first observation
[10,19,22]. Nevertheless we may still underestimate the benefit
associated with a higher CD4 cell count to some extent, possibly
because of infrequent updating in some patients but more likely
because of the considerable measurement error in CD4 cell counts
[21,23,24]. We did not adjust for primary prophylaxis as this is on
a causal pathway between a low CD4 cell count and outcome (see
[25]). The use of prophylactic drugs will result in an underestimate
of the benefit associated with a higher CD4 cell count for patients
with a low CD4 cell count relative to the benefit one would expect
in the absence of any prophylaxis.
Previous studies have shown an increased risk of AIDS or death
with lower time updated CD4 cell count in untreated patients and
in treatment experienced patients [19,26], and with lower CD4
cell count at the start of treatment or after 6 mo of treatment in
treatment-naive patients [3,4,22]. In all these studies, CD4 cell
count was the strongest prognostic factor for disease progression;
viral load was at best only weakly predictive of progression in
models with time updated CD4 cell counts [19,21]. Here we show
an increased risk of AIDS or death with lower time updated CD4
cell count in successfully treated patients. The mortality rate in this
study was 4.8 per 1,000 y of suppression; lower than the rate of 12
or 14 per 1,000 y in treatment-naive patients starting cART
[3,27]. The event rates in Tables 2–4 show that CD4 cell count
gradients are seen in unadjusted rates; otherwise these rates are of
limited value to clinicians because of differences between cohorts
in rates of AIDS and death, with differences probably due to
different methods of diagnosing disease and ascertaining death
[28]. However the association between CD4 cell count and AIDS
or death appears much more stable across cohorts [28], consistent
with our analytic approach where each cohort had a separate
baseline hazard but covariate effects were assumed to be the same
in each cohort.
The results of this study provide further indirect evidence for
starting cART when a patient’s CD4 cell count is between 350 and
500 cells/ml [29,30]. In this study the benefits associated with a
higher CD4 cell count were similar over a range of CD4 cell
counts from 200 to 500 cells/ml. Above a count of 500 cells/ml, a
higher CD4 cell count was associated with a slightly reduced risk
of an AIDS event but had little association with the risk of death;
hence even earlier treatment with a CD4 cell count above 500
cells/ml might be appropriate for patients with characteristics
associated with slower immune recovery—older patients, those
with a drug addiction, or co-infected with viral hepatitis [31–33];
such patients had a greater risk of progression in our study. A
higher CD4 cell count was also associated with a reduced risk of
death from causes thought unrelated to HIV. This finding suggests
that the distinction between causes of death related and unrelated
to HIV is rather arbitrary in successfully treated patients, and that
there is a need for more sophisticated recording and review of
causes of death to avoid underestimating the burden of HIV
infection [28,34,35].
In several studies, a CD4 cell count of around 200 cells/ml has
been seen as an important threshold [3,21,22]. The strength of
time updated CD4 cell count as a prognostic factor for survival has
led to a suggestion that ‘‘there is a threshold beyond which
immune reconstitution may be compromised’’ [22]. Others argue
that patients starting treatment with low counts do not seem to
remain disadvantaged if the CD4 cell count at the start of
treatment is not predictive of survival once adjusted for a value at
6 mo [4]. We see our results—with a higher CD4 cell count
becoming even more important over time for patients with low
CD4 cell counts—as more consistent with the idea of lasting
damage below some threshold from which recovery is difficult
[18,36]. Many patients starting therapy with a CD4 cell count
below 200 cells/ml never achieve a normal CD4 cell count even
after 10 y of otherwise effective antiretroviral therapy [37],
although this failure to recover could be due to factors other than
a low CD4 cell count per se. Various treatment intensification
strategies have failed to show any benefit in patients with low CD4
cell counts [38,39]. Despite improvements, the majority of patients
in resource-limited settings still start therapy with a CD4 cell count
below 200 cells/ml [40], so that along with improved access to
treatment, earlier diagnosis and earlier treatment are also needed
to reduce mortality in this setting [41].
This study shows that even though new AIDS events and death
are uncommon in patients on cART with a suppressed viral load,
these patients still benefit from a higher CD4 cell count. There is
support in this study for starting cART when a patient’s CD4 cell
count is between 350 and 500 cells/ml and for continued vigilance
when treating patients with sustained viral suppression but a low
CD4 cell count.
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Editors’ Summary
Background. Currently, about 34 million people are
infected with HIV and every year nearly 3 million people
are newly infected with this virus, which causes AIDS. Most
people do not become ill immediately after infection with
HIV although some develop a short, flu-like illness (a
‘‘seroconversion’’ illness). The next stage of HIV infection,
which may last up to 10 years, also has no major symptoms
but, during this stage, HIV slowly destroys immune system
cells (including CD4 cells, a type of lymphocyte). Eventually,
the immune system can no longer fight off infections by
other disease-causing organisms and HIV-positive people
then develop one or more AIDS-defining condition(s),
including severe but unusual infections, Kaposi sarcoma (a
skin cancer), and non-Hodgkin lymphoma (a cancer of the
lymph nodes). Many of these AIDS-defining conditions are
life-threatening and, in the past, HIV-positive people died on
average within 10 years of infection. Nowadays, although
there is still no cure for HIV infection, combination
antiretroviral therapy (cART; a cocktail of powerful
antiretroviral drugs) has turned HIV/AIDS into a chronic,
treatable condition, at least in developed countries.
Why Was This Study Done? Most HIV-positive adults
achieve viral suppression within a year of starting cART. That
is, the number of copies of the virus in their blood drops to
below 50 copies/ml. But what is the likely clinical outcome
for patients who achieve viral suppression and what is their
risk of developing a new AIDS-defining condition or of
dying? For people starting cART for the first time, the
number of CD4 cells in the blood when cART is initiated
provides a strong indication of an individual’s likely clinical
outcome. Specifically, people who start cART when they
have a high CD4 cell count tend to do better than people
who start treatment when they have a low CD4 cell count. In
this study, the researchers use data collected by the
Collaboration of Observational HIV Epidemiological
Research in Europe (COHERE) to estimate the association
between CD4 cell count and progression to a new AIDS-
defining event or death among patients who have achieved
viral suppression while on cART.
What Did the Researchers Do and Find? The researchers
identified more than 75,000 patients in the COHERE database
who, between them, had had more than 104,000 episodes
(periods) of viral suppression while on cART and who had
had their CD4 cell count determined shortly before or during
their viral suppression episodes. The researchers then used
stratified multivariate Cox models (a type of statistical
analysis method) to estimate the association between CD4
cell counts and the occurrence of a new AIDS-defining event
or death. Among the patients included in the study, the
mortality (death) rate was 4.8 per 1,000 years of viral
suppression. The highest rates of new AIDS-defining events
or death were seen in those patients with less than 50 CD4
cells/ml blood and a higher CD4 cell count was associated
with a reduced risk of a new AIDS-defining event or death.
Finally, among those patients with a CD4 cell count below
200 cells/ml, the risk of progression decreased over time for
those patients with higher CD4 cell counts.
What Do These Findings Mean? These findings suggest
that, although new AIDS-defining events and death are
uncommon among patients whose viral load is suppressed by
cART, the risk of a new AIDS-defining event or death follows a
CD4 cell count gradient with the patients with the highest
CD4 cell counts having the lowest risk of a new AIDS-defining
event or death. The findings also suggest that higher CD4 cell
counts provide the greatest benefit for patients with a CD4
cell count below 200 cells/ml blood. These findings have two
main clinical implications. First, they add to the evidence that
suggests that, to facilitate immune system recovery, cART
should be started when a patient’s CD4 cell count is between
350 and 500 cells/ml blood, the current recommended range
for cART initiation. Unfortunately, most patients in resource-
limited settings only start cART when their CD4 cell count is
below 200 cells/ml. Second, these findings suggest that
patients with sustained viral suppression but low CD4 cell
counts should be monitored regularly to ensure that any life-
threatening AIDS-defining events are dealt with quickly and
effectively.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001194.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including detailed
information on HIV treatment and care (in English and
Spanish)
N The World Health Organization’s 2010 antiretroviral
therapy guidelines provide recommendations on when
to initiate cART
N Information about COHERE is available
N Patient stories about living with HIV/AIDS are available
through Avert and through the charity website
Healthtalkonline
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